COVID-19 Antiviral Treatments: What's Available and Who Qualifies

For most people, COVID-19 still means a few uncomfortable days at home. But for people at higher risk of severe illness, antiviral treatments are available on the NHS that can meaningfully reduce the chance of the infection becoming serious, provided they're started quickly enough after symptoms begin.

What antiviral treatments are available

The NHS provides two main antiviral medicines for eligible patients with COVID-19. Nirmatrelvir plus ritonavir, sold as Paxlovid, is an oral treatment taken as a course of tablets and is generally the first-line option. Molnupiravir, sold as Lagevrio, is an alternative oral treatment offered to patients who can't take Paxlovid, typically due to drug interactions or underlying health issues such as severe kidney or liver disease.

Both work by interfering with the virus's ability to replicate in the body, which is why timing matters so much: they're designed to be started early in the course of illness, before the virus has had the chance to cause more significant harm.

Who is eligible

To qualify for an antiviral treatment assessment, you generally need to meet all of the following: be aged 12 or over, have COVID-19 symptoms, have a positive COVID-19 test result and be considered at highest risk of becoming seriously ill from the infection.

Eligibility for the "highest risk" category has expanded over time and, as of 2026, covers a substantial group beyond the severely immunocompromised, including adults aged 85 and over, care home residents aged 70 and over, people with end-stage heart failure and those on organ transplant waiting lists, alongside people with conditions such as Down syndrome, certain cancers, sickle cell disease, chronic kidney disease at stages 4 to 5, severe liver disease, HIV or AIDS with a weakened immune system and certain neurological or lung conditions.

How to access treatment

The process now generally requires you to take the first step yourself rather than waiting to be contacted. If you're in an eligible group, it's worth keeping rapid lateral flow tests at home, since free kits remain available from pharmacies for people who qualify for antiviral treatment. Test as soon as you develop symptoms and, if positive, contact your GP surgery, NHS 111 or a hospital specialist promptly, since treatment needs to start quickly to be effective.

Many local NHS Integrated Care Boards now run an online self-referral portal specifically for this purpose, often described as a "COVID Medicines Delivery Unit" or CMDU. Searching for your local ICB's CMDU self-referral page is often the fastest route to an assessment if you test positive and believe you're eligible.

Why timing matters so much

Antiviral treatments for COVID-19 are most effective when started as early as possible after symptoms begin, generally within the first few days. This is why eligible patients are advised to test immediately when symptoms start rather than waiting to see if things get worse and why prompt contact with a GP, NHS 111 or hospital specialist is emphasised throughout NHS guidance on accessing these treatments.

What if you test negative but still have symptoms?

If you're in an eligible group, have symptoms, but test negative on a lateral flow test, NHS guidance generally recommends testing again over the following days, typically across three consecutive days, since a single negative result early in an infection doesn't always rule out COVID-19. This matters particularly for people in the highest-risk categories, where missing a genuine case could mean missing the window for effective antiviral treatment.

Are these treatments the same as the vaccine?

No. Vaccines are given before infection to reduce the risk of catching COVID-19 or developing severe illness if you do. Antiviral treatments are given after a positive test and active symptoms, specifically to reduce the severity of an infection that's already happening. The two are complementary rather than interchangeable and being vaccinated doesn't remove the value of antiviral treatment if you're in an eligible group and do test positive.

How antiviral eligibility has changed since the early pandemic

Access to COVID-19 antivirals looked quite different in the earlier years of the pandemic, when eligibility was narrower and the NHS often proactively contacted people identified as high-risk through GP records. That automatic outreach model has largely been phased out as the NHS has shifted more responsibility onto patients to self-report a positive test and request an assessment, which is a significant practical change for anyone who was used to the earlier system.

At the same time, the list of qualifying health conditions has generally expanded rather than narrowed, with NICE widening access to cover several million more people by 2026 than were originally eligible when Paxlovid was first introduced. The combination of broader eligibility but less automatic outreach makes it particularly important for anyone who might qualify, or who cares for someone who might, to know in advance how their local self-referral process works, rather than trying to work it out for the first time while unwell.

A quick recap

Antiviral treatments including Paxlovid and molnupiravir remain available on the NHS for people at highest risk of severe COVID-19, with 2026 eligibility covering a wider group than earlier in the pandemic. Getting tested promptly when symptoms start and contacting your GP, NHS 111 or your local self-referral service quickly gives these treatments the best chance of working.

Frequently asked questions

Are COVID-19 antivirals free on the NHS?

Yes, for patients who meet the eligibility criteria, antiviral treatment is provided free through the NHS following an appropriate assessment.

Can I request antiviral treatment if I'm not in a high-risk group?

Antiviral treatment through the NHS pathway is specifically reserved for people assessed as being at highest risk of severe illness. If you're unsure whether you qualify, your GP or NHS 111 can assess your individual circumstances.

How quickly do I need to start treatment after symptoms begin?

Antivirals are most effective when started as early as possible, so testing immediately when symptoms appear and contacting a healthcare provider straight away gives you the best chance of qualifying in time.

Do antiviral treatments have side effects?

Like any medicine, antivirals can cause side effects and may interact with other medications you're taking, which is part of why a clinical assessment is required before they're prescribed rather than being available over the counter.

What happens if I don't qualify for antiviral treatment?

If you're not in a high-risk group, standard supportive care, rest, fluids and over-the-counter symptom relief, remains the recommended approach, in the same way it would be for most other people with COVID-19.

Can I keep antiviral tablets at home in advance, like I can with lateral flow tests?

No. Antivirals require a clinical assessment and prescription tied to a confirmed positive test and active symptoms, so unlike lateral flow tests, they can't be stockpiled at home in advance of an infection.

Can I take antivirals alongside other regular medications?

This depends on the specific medications involved, since Paxlovid in particular has known interactions with a range of common drugs, which is exactly why a clinical assessment checks your current medications before a prescription is issued. Bringing an up-to-date, written list of everything you're currently taking, including over-the-counter medicines, herbal remedies and supplements, to that assessment can help it go more smoothly and quickly.